Research ArticleTheranostics
The Effect of Total Tumor Volume on the Biologically Effective Dose to Tumor and Kidneys for 177Lu-Labeled PSMA Peptides
Nusrat J. Begum, Anne Thieme, Nina Eberhardt, Robert Tauber, Calogero D’Alessandria, Ambros J. Beer, Gerhard Glatting, Matthias Eiber and Peter Kletting
Journal of Nuclear Medicine June 2018, 59 (6) 929-933; DOI: https://doi.org/10.2967/jnumed.117.203505
Nusrat J. Begum
1Department of Nuclear Medicine, Universität Ulm, Ulm, Germany
Anne Thieme
2Department of Nuclear Medicine, Klinikum Rechts der Isar, Technische Universität München, Munich, Germany; and
Nina Eberhardt
2Department of Nuclear Medicine, Klinikum Rechts der Isar, Technische Universität München, Munich, Germany; and
Robert Tauber
3Department of Urology, Klinikum Rechts der Isar, Technische Universität München, Munich, Germany
Calogero D’Alessandria
2Department of Nuclear Medicine, Klinikum Rechts der Isar, Technische Universität München, Munich, Germany; and
Ambros J. Beer
1Department of Nuclear Medicine, Universität Ulm, Ulm, Germany
Gerhard Glatting
1Department of Nuclear Medicine, Universität Ulm, Ulm, Germany
Matthias Eiber
2Department of Nuclear Medicine, Klinikum Rechts der Isar, Technische Universität München, Munich, Germany; and
Peter Kletting
1Department of Nuclear Medicine, Universität Ulm, Ulm, Germany
Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 59, Issue 6
June 1, 2018
The Effect of Total Tumor Volume on the Biologically Effective Dose to Tumor and Kidneys for 177Lu-Labeled PSMA Peptides
Nusrat J. Begum, Anne Thieme, Nina Eberhardt, Robert Tauber, Calogero D’Alessandria, Ambros J. Beer, Gerhard Glatting, Matthias Eiber, Peter Kletting
Journal of Nuclear Medicine Jun 2018, 59 (6) 929-933; DOI: 10.2967/jnumed.117.203505
The Effect of Total Tumor Volume on the Biologically Effective Dose to Tumor and Kidneys for 177Lu-Labeled PSMA Peptides
Nusrat J. Begum, Anne Thieme, Nina Eberhardt, Robert Tauber, Calogero D’Alessandria, Ambros J. Beer, Gerhard Glatting, Matthias Eiber, Peter Kletting
Journal of Nuclear Medicine Jun 2018, 59 (6) 929-933; DOI: 10.2967/jnumed.117.203505
Jump to section
Related Articles
Cited By...
- The Impact of Peptide Amount on Tumor Uptake to Assess PSMA Receptor Saturation on 68Ga-PSMA-11 PET/CT in Patients with Primary Prostate Cancer
- Combined Targeted Radiopharmaceutical Therapy and Immune Checkpoint Blockade: From Preclinical Advances to the Clinic
- Synthesis and Preclinical Evaluation of 177Lu-Labeled Radiohybrid PSMA Ligands for Endoradiotherapy of Prostate Cancer
- Kidney Doses in 177Lu-Based Radioligand Therapy in Prostate Cancer: Is Dose Estimation Based on Reduced Dosimetry Measurements Feasible?
- Effect of Tumor Perfusion and Receptor Density on Tumor Control Probability in 177Lu-DOTATATE Therapy: An In Silico Analysis for Standard and Optimized Treatment
- Investigating PSMA-Targeted Radioligand Therapy Efficacy as a Function of Cellular PSMA Levels and Intratumoral PSMA Heterogeneity
- Modeling and Predicting Tumor Response in Radioligand Therapy
- The Relevance of Dosimetry in Precision Medicine